[
  {
    "ticker": "LML",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964026",
    "id": "02964026",
    "pages": 3,
    "price_sensitive": false,
    "date": "20250701",
    "time": "0815",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l99qgv5fnv48.pdf",
    "summary": "<h3>Summary of ASX Announcement:</h3>\n<ul>\n<li><strong>Upcoming Investor Webinar</strong> (8 July 2025, 11:00 AEST) \u2013 Focus on:  </li>\n<li>Strategic drill program at <strong>Minbrie copper-zinc project</strong> (SA).  </li>\n<li>\n<p>Updates on broader project portfolio.  </p>\n</li>\n<li>\n<p><strong>Minbrie Project Key Details</strong>:  </p>\n</li>\n<li><strong>Resource Potential</strong>: 7km strike, shallow (&lt;300m) open-pit potential.  </li>\n<li><strong>Highlighted Drill Result</strong>: 29.5m @ 0.8% Cu, 7.5% Pb, 1.9% Zn, 9.0 g/t Ag.  </li>\n<li><strong>Infrastructure</strong>: Proximity to Port Pirie Smelter (~265km), 100% owned by LML.  </li>\n</ul>\n<p><em>(No capital raising, financials, or material catalysts disclosed beyond exploratory updates.)</em>  </p>\n<p><strong>Conclusion</strong>: Operational update only; no immediate trading-impacting data.</p>",
    "usage": {
      "prompt_tokens": 1297,
      "completion_tokens": 202,
      "total_tokens": 1499,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-06-30T22:17:52.717248"
  },
  {
    "ticker": "SUN",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964022",
    "id": "02964022",
    "pages": 3,
    "price_sensitive": false,
    "date": "20250701",
    "time": "0804",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l99d2btnh1vh.pdf",
    "summary": "<ul>\n<li><strong>FY26 Reinsurance Program Update</strong>:  </li>\n<li><strong>Structure</strong>: Main catastrophe cover ($500M\u2013$6.3B), structured multi-year solution (replaces Group cover), NZ buydown cover (NZ$200M\u2013$350M).  </li>\n<li>\n<p><strong>Key Changes</strong>:  </p>\n<ul>\n<li><strong>Lower Cost</strong>: Total program cost expected to be below FY25 due to rate reductions.  </li>\n<li><strong>Retention</strong>: Maximum event retention unchanged at $350M for 1st/2nd events; 3rd/4th event dropdowns remain ($250M/$150M in Australia).  </li>\n<li><strong>New Features</strong>: Added 2nd reinstatement for $500M\u2013$1B layer; profit-sharing mechanism in structured cover (reinsurer losses capped at $600M over 3 years).  </li>\n</ul>\n</li>\n<li>\n<p><strong>Impact</strong>:  </p>\n</li>\n<li><strong>Earnings</strong>: No material change to risk retention or capital targets.  </li>\n<li><strong>Pricing</strong>: Reinsurance cost stability may support underlying insurance margin (10\u201312% target).  </li>\n<li>\n<p><strong>Capital Management</strong>: Excess capital return update to be provided with full-year results (August).  </p>\n</li>\n<li>\n<p><strong>Market Context</strong>: Reinsurance capacity increased for main catastrophe covers; pricing improved.  </p>\n</li>\n</ul>\n<p><strong>Note</strong>: Focus on cost reduction, margin stability, and capital return potential. Operational details (e.g., dropdowns) reflect risk management adjustments.  </p>\n<p><em>Summary excludes non-material commentary on strategic reviews, brokers, or NZ-specific dropdowns.</em></p>",
    "usage": {
      "prompt_tokens": 1549,
      "completion_tokens": 303,
      "total_tokens": 1852,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-06-30T22:17:31.455711"
  },
  {
    "ticker": "MPP",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964021",
    "id": "02964021",
    "pages": 2,
    "price_sensitive": true,
    "date": "20250701",
    "time": "0731",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l9932r1ktnvl.pdf",
    "summary": "<p><strong>Capital Raising Announcement:</strong><br />\n- <strong>Structure:</strong> Renounceable rights issue ($9m) + placement to Amari Metals Australia Pty Ltd ($6m min., up to $15m total).<br />\n- <strong>Total Raised:</strong> Minimum $15m, maximum $24m at $0.03 per share.<br />\n- <strong>Key Dates:</strong> Shareholder meeting expected late August 2025; documentation to be sent early August.<br />\n- <strong>New Cornerstone Investor:</strong> Amari Metals to own 51% post-completion.<br />\n- <strong>New Loan Facility:</strong> 3-year facility agreed (terms aligned with current pricing).<br />\n- <strong>Conditions:</strong> Shareholder approval, final documentation, and cross-completion required.</p>",
    "usage": {
      "prompt_tokens": 1161,
      "completion_tokens": 146,
      "total_tokens": 1307,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-06-30T22:17:25.197482"
  },
  {
    "ticker": "AFP",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964020",
    "id": "02964020",
    "pages": 4,
    "price_sensitive": false,
    "date": "20250701",
    "time": "0731",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l990zgn71gvv.pdf",
    "summary": "<p><strong>June Quarter FY 2026 Investor Update - Key Highlights:</strong>  </p>\n<ul>\n<li><strong>Combogesic IV\u00ae launch in Canada</strong> begins this month, targeting non-opioid pain management in a market growing at 6.1% CAGR (forecast to reach US$1.88B by 2030).  </li>\n<li><strong>US Maxigesic licensing agreement extended with Hikma Pharmaceuticals</strong>: Restructured profit-sharing (quarterly payments) and expanded marketing rights for Combogesic IV/Rapid.  </li>\n<li><strong>R&amp;D pipeline milestones</strong>:  </li>\n<li>Pre-IND filed for antibiotic eyedrop (targeting MRSA-resistant infections); IND targeted by year-end.  </li>\n<li>Pre-IND for Strawberry Birthmarks topical treatment and IND for novel iron injection planned by year-end.  </li>\n<li>Added improved formulation project (US$180M niche market potential).  </li>\n<li><strong>Paediatric Maxigesic IV study</strong> to commence, addressing unmet needs in hospital pain management.  </li>\n<li><strong>Global expansion</strong>: Further OTC and in-licensed product launches planned in FY26 across Canada, Singapore, Hong Kong, and other markets.  </li>\n</ul>\n<p><strong>No material financial data (e.g., cash balance) disclosed.</strong></p>",
    "usage": {
      "prompt_tokens": 2424,
      "completion_tokens": 243,
      "total_tokens": 2667,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-06-30T22:18:04.740111"
  },
  {
    "ticker": "AIA",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964018",
    "id": "02964018",
    "pages": 1,
    "price_sensitive": false,
    "date": "20250701",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l98wrcx6pw71.pdf",
    "summary": "<p>Understood. Please upload or paste the ASX announcement PDF text, and I will provide a concise, material-only summary based on its type and content.  </p>\n<p>If you cannot share the full document, specify the announcement type (e.g., Trading Halt, Capital Raising, Quarterly) and I\u2019ll adapt the template accordingly.  </p>\n<p><strong>Example Outputs:</strong>  </p>\n<ol>\n<li><strong>Trading Halt Request</strong>  </li>\n<li>\n<p>Reason: Pending announcement of a material capital raising.  </p>\n</li>\n<li>\n<p><strong>Capital Raising Announcement</strong>  </p>\n</li>\n<li>Structure: AUD 50M Placement + AUD 10M SPP.  </li>\n<li>\n<p>Key Dates: Ex-date (DD/MM), Record (DD/MM), Close (DD/MM).  </p>\n</li>\n<li>\n<p><strong>Quarterly Report (4C)</strong>  </p>\n</li>\n<li>Cash Balance: AUD 15.2M (prior: AUD 18.1M).  </li>\n<li>\n<p>Key Highlight: Quarterly revenue up 12% QoQ to AUD 5.3M.  </p>\n</li>\n<li>\n<p><strong>Other Announcement</strong>  </p>\n</li>\n<li>Major Asset Sale: AUD 100M divestment of [X] division.  </li>\n<li>Debt Facility: New AUD 75M secured loan at 6% margin.  </li>\n</ol>\n<p>Awaiting your input.</p>",
    "usage": {
      "prompt_tokens": 218,
      "completion_tokens": 259,
      "total_tokens": 477,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-06-30T22:17:06.035566"
  },
  {
    "ticker": "CNU",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964019",
    "id": "02964019",
    "pages": 4,
    "price_sensitive": false,
    "date": "20250701",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l98yw68lrr7b.pdf",
    "summary": "<ul>\n<li><strong>Redemption of Crown Funding Securities</strong>:  </li>\n<li><strong>CIP1 Equity Securities</strong>: 85,341,018 redeemed at NZ$1.00 per security (total <strong>NZ$85.3m</strong>).  </li>\n<li><strong>CIP1 Warrants</strong>: 7,561,881 cancelled at nil consideration.  </li>\n<li>\n<p><strong>CIP1 Debt Securities</strong>: NZ$85.3m repaid.  </p>\n</li>\n<li>\n<p><strong>Impact on Capital Structure</strong>:  </p>\n</li>\n<li>Redemption reduces unquoted equity securities by <strong>18.5%</strong> and warrants by <strong>43.3%</strong>.  </li>\n<li>\n<p>Remaining: 376,711,053 CIP1 Equity Securities and 9,903,147 CIP1 Warrants.  </p>\n</li>\n<li>\n<p><strong>Reason</strong>: Dividends became payable on portion of CIP1 Equity Securities; warrants expired.  </p>\n</li>\n</ul>\n<p><em>No material trading or liquidity impact identified (unquoted securities).</em></p>",
    "usage": {
      "prompt_tokens": 1792,
      "completion_tokens": 184,
      "total_tokens": 1976,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-06-30T22:17:57.952622"
  },
  {
    "ticker": "IFT",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964017",
    "id": "02964017",
    "pages": 6,
    "price_sensitive": false,
    "date": "20250701",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l98tml9jndtl.pdf",
    "summary": "<ul>\n<li><strong>Dividend Details</strong>:  </li>\n<li><strong>Type</strong>: Ordinary (unfranked)  </li>\n<li><strong>Amount</strong>: NZD 0.1325 per share (AUD 0.1229 equivalent)  </li>\n<li>\n<p><strong>Record Date</strong>: 12/6/2025 | <strong>Ex-Date</strong>: 11/6/2025 | <strong>Payment Date</strong>: 2/7/2025  </p>\n</li>\n<li>\n<p><strong>DRP Update</strong>:  </p>\n</li>\n<li><strong>Strike Price</strong>: NZD 10.42983548 (volume-weighted average, 16\u201330 June 2025, with 2% discount)  </li>\n<li><strong>Election Deadline</strong>: 13/6/2025, 15:00 NZ time  </li>\n<li>\n<p><strong>Eligibility</strong>: NZ/Australian residents only (unless discretion applied)  </p>\n</li>\n<li>\n<p><strong>Tax</strong>:  </p>\n</li>\n<li><strong>Withholding Tax</strong>: 15% for non-residents.  </li>\n<li><strong>Unfranked</strong>: 100% (no franking credits).  </li>\n</ul>\n<p><em>No other material information identified.</em></p>",
    "usage": {
      "prompt_tokens": 2312,
      "completion_tokens": 215,
      "total_tokens": 2527,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-06-30T22:17:11.845790"
  }
]